Chadi Nabhan, MD, MBA, FACP

Chadhi Nabhan, MD, MBA, FACP, is a hematologist/oncologist and award-winning host of the “Outspoken Oncology” and “Healthcare Unfiltered” podcasts.

Articles by Chadi Nabhan, MD, MBA, FACP

Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | July 26, 2024
Rami Komrokji, MD, describes incorporation of molecular data, tailoring treatment by disease risk, and new therapies in MDS.
Listen Now
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse Live | July 18, 2024
This episode explores questions in CLL with Mazyar Shadman, MD; Meghan Thompson, MD; Alan Skarbnik, MD during HOP Live 2024.
Naveen Pemmaraju, MDThe HemOnc Pulse Live | July 1, 2024
Dr. Pemmaraju discusses three major unanswered questions for myeloproliferative neoplasm researchers.
Sangeetha Venugopal, MDChronic Myeloid Leukemia | June 7, 2024
Sangeetha Venugopal, MD, engages outstanding issues in chronic myeloid leukemia treatment research.
Chadi Nabhan, MD, MBA, FACPVideo Insights | June 7, 2024
Himachandana Atluri, MD, describes the experience and ins and outs of becoming a new fellow.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse Live | May 31, 2024
Dr. Usmani offers his take on treating smoldering myeloma and using MRD as a prognostic factor.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse Live | May 24, 2024
Michael Bishop MD; Aaron Goodman, MD; and Rafael Fonseca, MD, discuss bispecifics in hematologic malignancies.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse Live | May 23, 2024
The panel discussed ALL treatment, associated toxicities, and the possibility of a chemotherapy-free approach.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | May 16, 2024
Dr. Hilal covers the debates surrounding MRD, whether he uses MRD to make treatment decisions, and more.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse Live | May 17, 2024
The panel discussed treatment options for Hodgkin lymphoma, maintenance therapy following autologous transplant, and more.
Chadi Nabhan, MD, MBA, FACPMyelodysplastic Syndromes | May 13, 2024
The panel mainly focused on how to define and classify MDS and CHIP, as well as how to treat low- and high-risk MDS.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse Live | June 10, 2024
The fellows discussed how to choose a career path, what makes a good mentor, and more.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse Live | July 26, 2024
Live from Chicago, the panel discussed unanswered questions in CAR-T.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse Live | May 8, 2024
Live in Chicago, this podcast episode features a panel discussion on unanswered questions in AML.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse: MRD | July 26, 2024
Alan Skarbnik, MD, and Manni Mohyuddin, MBBS, discuss the concept of MRD in hematologic malignancies.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | April 10, 2024
HMAs such as decitabine and cedazuridine (Inqovi) have become the “cornerstone” of treating high-risk patients.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | April 8, 2024
"Having something that could cure patients after failing CAR-T is huge,” host Dr. Chadi Nabhan said during the episode.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | March 28, 2024
It's many different diseases, and it falls across many different specialties, according to the Dr. Goodman.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse Live | May 8, 2024
Dr. Chadi Nabhan brings "The HemOnc Pulse" live to Chicago May 3-4.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse: MRD | July 26, 2024
Elias Jabbour, MD, joined "The HemOnc Pulse" to discuss the function of MRD in treating ALL.